Xenon Pharma Shares Jump After Epilepsy Treatment Phase 2 Data Meets Primary Endpoint

Xenon Pharmaceuticals Inc XENE has reported topline results from the Phase 2b X-TOLE trial evaluating XEN1101 as an adjunctive treatment in adult patients with focal epilepsy.
The trial met its primary efficacy endpoint with XEN1101, demonstrating a statistically significant and dose-dependent reduction from baseline in monthly focal seizure frequency compared to placebo.
The median percent reduction in monthly focal seizure frequency was 52.8% in the XEN1101 25 mg group, 46.4% in the XEN1101 20 mg group, and 33.2% in the XEN1101 10 mg group compared to 18.2% in the placebo group.
The percentage of subjects who achieved an over 50% reduction in monthly focal seizures was 54.5% in the XEN1101 25 mg group, 43.1% in the XEN1101 20 mg group, and 28.3% in the XEN1101 10 mg group compared to 14.9% in the placebo group. XEN1101 was generally well-tolerated.
The incidence of treatment-emergent adverse events (TEAEs) was higher in the treatment groups than in the placebo group.
The most common TEAEs across all XEN1101 dose groups were dizziness, drowsiness, fatigue, and headache.
Two TEAEs of urinary retention were reported, one of which required a dose reduction.
Price Action: XENE stock is up 67.90% at $26.10 during the market session on the last check Monday.